|Awarded On||February 21, 2019|
|Title||Off the Shelf CAR-NKT Cells for Treatment of Solid and Hematological Malignancy|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Principal Investigator/Program Director||Kurt Gunter|
|Cancer Sites||Leukemia, Lymphoma|
*Pending contract negotiation
Cell Medica’s novel approach uses healthy donor immune cells (off-the-shelf) modified to treat a variety of incurable tumors. Current CAR T cell products are “autologous,” where a patient’s own isolated T cells are modified by a “chimeric antigen receptor” targeting that patient’s cancer when administered to that patient.
While effective for some blood cancers (lymphoma/leukemia), these products have several issues. Patient response rates need improvement, even in lymphoma, and safety is problematic. Time needed to modify a sick patient’s cells (weeks) is too long even as some patients do not generate enough cells for treatment. Also, CAR T cells are less effective for solid tumors as the ...